- Home
- AURA vs SABR Comparison
AURA vs SABR Comparison
Compare AURA & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AURA | SABR |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.4M | 814.3M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AURA | SABR |
|---|---|---|
| Price | $6.41 | $1.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $20.00 | $1.50 |
| AVG Volume (30 Days) | 448.1K | ★ 6.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 283.56 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $3,866,956,000.00 |
| Revenue This Year | N/A | $7.51 |
| Revenue Next Year | N/A | $3.46 |
| P/E Ratio | ★ N/A | $84.00 |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $4.73 | $0.81 |
| 52 Week High | $9.54 | $3.46 |
Technical Indicators
Market Signals| Indicator | AURA | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 47.21 |
| Support Level | $5.81 | $1.49 |
| Resistance Level | $6.56 | $1.70 |
| Average True Range (ATR) | 0.34 | 0.12 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 19.95 | 35.80 |
Price Performance
Historical ComparisonAbout AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.